TU PORTAL ON-LINE

 BIBLIOGRAFIA DEPRESION  


  

  BiBliografía de la Depresión

• World Health Organization. Depression. Geneva. 2007. Citado 1 octubre 2007; Disponible en: http://www.who.int/mental_health/management/depression/definition/en/
• Murray CJ, López AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504.
• Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-105.
• Libro Verde. Mejorar la salud mental de la población. Hacia una estrategia de la Unión Europea en materia de salud mental. In: Comisión de las Comunidades Europeas; 2005. p. 484 final.
• Haro JM, Palacin C, Vilagut G, Martínez M, Bernal M, Luque I, et al. Prevalencia de los trastornos mentales y factores asociados: resultados del estudio ESEMeD-Espana. Med Clin (Barc) 2006;126(12):445-51.
• Crespo D, Gil A, Porras Chavarino A, Grupo De Investigación en Depresión y Psiquiatría de Enlace. Prevalencia de los trastornos depresivos en psiquiatría de enlace. Actas Esp Psiquiatr 2001;29(2):75-83.
• Barro Lugo S, Saus Arús M, Barro Lugo A, M. FM. Depresión y ansiedad en inmigrantes no regularizados. Aten Primaria 2004;34(9):504.
• Instituto Nacional de Estadística. Defunciones según la causa de muerte. Internet. Instituto Nacional de Estadística. 2007. Citado 1 octubre 2007; Disponible en: http://www.ine.es
• Subgrupos ATC y principios activos de mayor consumo en el Sistema Nacional de Salud en 2005. Inf Ter Sist Nac Salud 2006;30:42-9.
• Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12(1):19-29.
• Aragonés Benaiges E, Gutiérrez Pérez M, Pino Fortuny M, Lucena Luque C, Cervera Virgili J, I GE. Prevalencia y características de la depresión mayor y la distimia en atención primaria. Aten Primaria 2001;27(9):623-8.
• Aragonés E, Pinol JL, Labad A, Folch S, Melich N. Detection and management of depressive disorders in primary care in Spain. Int J Psychiatry Med 2004; 34 (4):331-43.
• Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999;60 Suppl 7:4-9; discussion 10-1.
• Aragonés E, Pinol JL, Labad A. The overdiagnosis of depression in non-depressed patients in primary care. Fam Pract 2006;23(3):363-8.
• Grupo VPM- SNS. Variaciones en la práctica médica de salud mental. Atlas var. práct. méd. sist. nac. salud 2007.
• Harman J, Edlund M, Fortney J. Disparities in the adequacy of depression treatment in the United Status. Psychiatr Serv 2004;55(12):1379-85.
• Villava Quintana E, Caballero Martínez L. Estudio sobre el uso y seguimiento del tratamiento con antidepresivos realizado por los médicos de Atención Primario. SEMERGEN 2006;32(9):427-32.
• Alberdi Sudupe J, Taboada O, Castro Dono C. Depresión. Guías clínicas. Fisterra. 2003. Citado 1 octubre 2007. Disponible en:http://www.fisterra.com/guias2/depresion.asp
• Geddes J, Butler R, Hatcher S, Cipriani A, Price J, Carney S, et al. Depression in adults. Clin Evid 2006(15):1366-406.
• Ingram RE, Ritter J. Vulnerability to depression: cognitive reactivity and parental bonding in high-risk individuals. J Abnorm Psychol. 2000 Nov;109(4):588-96.
• Regier DA, Boyd JH, Burke JD, Jr., Rae DS, Myers JK, Kramer M, et al. One-month prevalence of mental disorders in the United States. Based on fi ve Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988;45(11):977-86.
• Serby M, Yu M. Overview: depression in the elderly. Mt Sinai J Med 2003;70 (1):38-44.
• Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan K, et al. The MINI International Neuropsychiatric Interview (M.I.N.I.) A Short Diagnostic Structured Interview: Reliability and Validity According to the CIDI. Eur Psychiatry 1997;12:224-31.
• Ferrando L F-AL, Soto M, Bobes J, Soto O, Franco L, Gubert J. M.I.N.I.Mini International Neuropsychiatric Interview. Versión en español 5.0.0.DSM-IV. Instituto IAP, Madrid, 1998.
• NICE. Depression: management of depression in primary and secondary care: National Clinical Practice Guideline number 23; 2004 December 2004.
• Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52 Suppl:28-34.
• Organización Mundial de la Salud. Décima Revisión de la Clasificación Internacional de Enfermedades. CIE-10. Trastornos mentales y del comportamiento. Madrid: Meditor; 1992.
• American Psychiatric Association. DSM-IV-TR Manual diagnóstico y estadístico de los trastornos mentales IV. Barcelona: Masson; 2003.
• Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. Am J Psychiatry 2006;163(1):115-24.
• Hamalainen J, Kaprio J, Isometsa E, Heikkinen M, Poikolainen K, Lindeman S, et al. Cigarette smoking, alcohol intoxication and major depressive episode in a representative population sample. J Epidemiol Community Health 2001;55(8):573-6.
• Turner RJ, Lloyd DA. Stress burden and the lifetime incidence of psychiatric disorder in young adults: racial and ethnic contrasts. Arch Gen Psychiatry 2004;61(5):481-8.
• Weissman MM, Wickramaratne P, Nomura Y, Warner V, Pilowsky D, Verdeli H. Offspring of depressed parents: 20 years later. Am J Psychiatry 2006;163(6):1001-8.
• Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157(10):1552-62.
• Weissman MM, Wickramaratne P, Nomura Y, Warner V, Verdeli H, Pilowsky DJ, et al. Families at high and low risk for depression: a 3-generation study. Arch Gen Psychiatry 2005;62(1):29-36.
• Lieb R IB, Hofler M, Pfister H, Wittchen H. Parenteral major depression and the risk of depression and other mental disorders in offspring: a prospective-longitudinal community study. Arch Gen Psychiatry 2002;59:365-74.
• Cervilla JA, Rivera M, Molina E, Torres-González F, Bellon JA, Moreno B, et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am J Med Genet B Neuropsychiatr Genet 2006;141(8):912-7.
• Eccleston D, Scott J. Treatment, prediction of relapse and prognosis of chronic primary major depression. Int Clin Psychopharmacol 1991;6 Suppl 2:3-10.
• Wilhelm K, Parker G, Dewhurst-Savellis J, Asghari A. Psychological predictors of single and recurrent major depressive episodes. J Affect Disord 1999;54(1-2):139-47. 44. Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major depression: a Swedish longitudinal, population-based twin study. Arch Gen Psychiatry 2006;63(10):1113-20.
• Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major depression: a Swedish longitudinal, population-based twin study. Arch Gen Psychiatry 2006;63(10):1113-20.
• Fogel J, Eaton WW, Ford DE. Minor depression as a predictor of the first onset of major depressive disorder over a 15-year follow-up. Acta Psychiatr Scand 2006;113(1):36-43.
• Goodwin RD, Fergusson DM, Horwood LJ. Panic attacks and the risk of depression among young adults in the community. Psychother Psychosom 2004;73(3):158-65.
• Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003;60(8):1308-12.
• King M, Weich S, Torres F, Svab I, Maaroos H, Neeleman J, et al. Prediction of depression in European general practice attendees: the PREDICT study. In: BMC Public Health; 2006. p. 6(1):6.
• Druss BG, Hoff RA, Rosenheck RA. Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults. J Clin Psychiatry 2000;61(3):234-7; quiz 238-9.
• Lecrubier Y. Is depression under-recognised and undertreated? Int Clin Psychopharmacol 1998;13 Suppl 5:S3-6.
• Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies. Br J Gen Pract 2007;57(535):144-51.
• Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136(10):765-76.
• MacMillan HL, Patterson CJ, Wathen CN, Feightner JW, Bessette P, Elford RW, et al. Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2005;172(1):33-5.
• Gilbody SM, House A, Sheldon TA. Instrumentos de cribaje (screening) y detección de casos para la depresión. En. Oxford: Update Software Ltd; 2007.
• Gilbody SM, House AO, Sheldon TA. Routinely administered questionnaires for depression and anxiety: systematic review. BMJ 2001;322(7283):406-9.
• Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord 2007;101(1-3):27-34.
• Nieto Rodríguez E, Vieta Pascual E. La conducta suicida en los trastornos afectivos. En: Ros Montalbán S, editor. La conducta suicida. Madrid: Arán; 1998. p. 99-121.
• Möller HJ. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl. 2003;(418):73-80.
• Rutz W. Preventing suicide and premature death by education and treatment. J Aff ect Disord. 2001;Jan;62(1-2):):123-9.
• Gibb BE, Alloy LB, Abramson LY, Rose DT, Whitehouse WG, Hogan ME. Childhood maltreatment and college students' current suicidal ideation: a test of the hopelessness theory. Suicide Life Threat Behav. 2001;31(4):405-15.
• Sokero TP, Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Isometsa ET. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. Br J Psychiatry 2005;186:314-8.
• Oquendo MA, Bongiovi-Garcia ME, Galfalvy H, Goldberg PH, Grunebaum MF, Burke AK, et al. Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. Am J Psychiatry 2007;164(1):134-41.
• Dumais A, Lesage AD, Alda M, Rouleau G, Dumont M, Chawky N, et al. Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry 2005;162(11):2116-24.
• Coryell W, Young EA. Clinical predictors of suicide in primary major depressive disorder. J Clin Psychiatry 2005;66(4):412-7.
• Furukawa T, McGuire H, Barbui C. Dosis bajas de antidepresivos tricíclicos para la depresión (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). 2003.
• Moncrieff J, Wessely S, Hardy R. Placebos activos versus antidepresivos para la depresión (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
• Arroll B, Macgillivray S, Ogston S, Reid I, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis.Annals of Family Medicine 2005;3(5), p. 449-456.
• Williams JW, Jr., Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132(9):743-56.
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63(4):331-6.
• Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18(4):211-7.
• Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17(3):95-102.
• Ballesteros J, Callado LF, Gutierrez M. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol 2007;27(2):219-21.
• Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004;10(1):23-44.
• Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39(11):1798-807.
• Montgomery S, Ferguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 2003;23(1):45-50.
• Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22(4):393-9.
• Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. Fluoxetina versus otros tipos de farmacoterapia para la depresión (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.) 2007.
• Gartlehner G, Hansen R, Thieda P, DeVeaugh-Geiss A, Gaynes B, Krebs E, et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Internet. Agency for Health Care Research and Quality, 2007citado 1 octubre 2007. Disponible en: http://effectivehealthcare.ahrq.gov/repFiles/Antidepressants_Final_Report.pdf
• Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006;20(1):91-6.
• Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 2006;95(1 3):119-123.
• Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: A double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 2006;26(2):121-127.
• Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000;157(9):1423-8.
• Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63(11):1217-23.
• Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A metaanalysis. J Clin Psychiatry 2005;66(2):148-58.
• Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334(7587):242.
• US Food and Drug Administration. Antidepressant use in children, adolescents, and adults. Internet. US Food and Drug Administration. 2004. Actualizado 2 May 2007, citado 1 octubre 2007; Disponible en: http://www.fda.gov/cder/drug/antidepressants/default.htm
• Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330(7488):385.
• Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63(3):332-9.
• Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: A double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006;26(1):75-78.
• Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, doubleblind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2006;22(9):1703-13.
• Institute for Clinical Systems Improvement (ICSI), editor. Health care guideline: major depression in adults in primary care.S 9th ed ed. Bloomington, MN: Institute for Clinical Systems Improvement; (ICSI); 2004.
• Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004;38(6):389-407.
• Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361(9358):653-61.
• Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fl uoxetine treatment. Am J Psychiatry 1998;155(9):1247-53.
• Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998;5(6):293-306.
• Gilaberte I, Montejo AL, de la Gandara J, Perez-Sola V, Bernardo M, Massana J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001;21(4):417-24.
• McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression.Am J Psychiatry 2006;163(9):1542-8.
• Vallejo Ruiloba J. Consenso. Tratamiento de las depresiones. Barcelona: Ars Médica;2005.
• Menza M. STAR*D: the results begin to roll in. Am J Psychiatry 2006;163(7):1123.
• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163(11):1905-17.
• Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255(6):387-400.
• Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressantresistant chronic depression. Arch Gen Psychiatry 2002;59(3):233-9.
• Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 1999;175:12-6.
• Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78(6):676-83.
• Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163(7):1161-72.
• McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163(9):1531-41; quiz 1666.
• Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 2005;89(1-3):1-11.
• Joff e RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50(5):387-93.
• Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163(9):1519-30; quiz 1665.
• Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefi t from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001;62(6):448-52.
• Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006;26(6):653-6.
• Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354(12):1243-52.
• Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fl uoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23(6):364-72.
• Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68(2):224-36.
• Hamilton KE, Dobson KS. Cognitive therapy of depression: pretreatment patient predictors of outcome. Clin Psychol Rev 2002;22(6):875-93.
• Beck A, Rush A. Cognitive therapy of depression. New York: Guilford Press; 1979.
• Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitivebehavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006 Jan;26(1):17-31.
• Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006;74(4):658-70.
• DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62(4):409-16.
• Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342(20):1462-70.
• Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68(4):615-23.
• Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, et al. Cognitive therapy versus medication in augmentation and switch strategies as secondstep treatments: a STAR*D report. Am J Psychiatry 2007;164(5):739-52.
• Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry 2005;66(4):455-68.
• Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, et al. Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol 2005;73(4):647-57.
• Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry 2002;159(8):1354-60.
• Klerman G, Weissman M, Rousanville B. Interpersonal psychotherapy of Depression.New York: Basic Books; 1984.
• de Mello MF, de Jesus Mari J, Bacaltchuk J, Verdeli H, Neugebauer R. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 2005;255(2):75-82.
• Frank E, Kupfer DJ, Buysse DJ, Swartz HA, Pilkonis PA, Houck PR, et al. Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 2007;164(5):761-7.
• Nezu AM. Efficacy of a social problem-solving therapy approach for unipolar depression. J Consult Clin Psychol 1986;54(2):196-202.
• Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a meta-analysis. Eur Psychiatry 2007;22(1):9-15.
• Pérez M, García J. Tratamientos psicológicos eficaces para la depresión. Psicothema 2001;13(3):493-510.
• Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46 Suppl 1:38S-58S.
• Department of Veterans Aff airs/Department of Defense (VA/DoD). Clinical practice guideline for the management of major depressive disorder in adults. Virginia: West Virginia Medical Institute; 2000.
• Sociedad Española de Psiquiatría. Consejo español sobre la terapia electroconvulsiva (TEC), 1999. Citado 1 octubre 2007; Disponible en: http://www.medicinainformacion.com/documentos/consensotec.pdf
• Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 2005;9(9):1-156, iii-iv.
• Tharyan P, Adams C. Terapia electroconvulsiva para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.), 2005.
• UK ECT Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361(9360):799-808.
• Rose D, Fleischmann P, Wykes T, Leese M, Bindman J. Patients' perspectives on electroconvulsive therapy: systematic review. BMJ 2003;326(7403):1363.
• Rubin EH, Kinscherf DA, Figiel GS, Zorumski CF. The nature and time course of cognitive side effects during electroconvulsive therapy in the elderly. J Geriatr Psychiatry Neurol 1993;6(2):78-83.
• Bhatia SC, Baldwin SA, Bhatia SK. Electroconvulsive therapy during the third trimester of pregnancy. J Ect 1999;15(4):270-4.
• Echevarría Moreno M, Martín Muñoz J, Sánchez Valderrabanos J, Vázquez Gutiérrez T. Electroconvulsive therapy in the first trimester of pregnancy. J ECT 1998;14(4):251-4.
• Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003;19(3):139-47.
• Gould R, Clum G. A meta-analysis of self-help treatment approaches. Clin Psychol Rev 1993;13:169-86.
• Burns D. Sentirse bien. Una nueva terapia para las depresiones. Barcelona: Paidós; 1999.
• Holdsworth N, Paxton R. Managing anxiety and depression. London: Mental Health Foundation; 1999.
• Lewinsohn P, Forster R, Youngsen M. Control your depression. Alaska: Fireside; 1992.
• Gregory R, Canning S, Lee T, Wise JC. Cognitive bibliotherapy for depression: a metaanalyisis.Prof Psychol 2004;35(3):275-9.
• Salkovskis P, Rimes K, Stephenson D, Sacks G, Scott J. A randomized controlled trial of the use of self-help materials in addition to standard general practice treatment of depression compared to standard treatment alone. Psychol Med 2006;36(3):325-33.
• den Boer PCAM WD, Russo S, van den Bosch RJ. Paraprofesionales para el tratamiento de la ansiedad y los trastornos depresivos. En: La Biblioteca Cochrane Plus, 2007 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com (Traducida de The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). .
• Houston TK, Cooper LA, Ford DE. Internet support groups for depression: a 1-year prospective cohort study. Am J Psychiatry 2002;159(12):2062-8.
• Tuesca-Molina R, Fierro Herrera N, Molinares Sosa A, Oviedo Martínez F, Polo Arjona Y, Polo Cueto J, et al. Los grupos de socializacion como factor protector contra la depresion en personas ancianas. Baranquilla, Colombia. Rev Esp Salud Publica 2003;77(5):595-604.
• Cheung A, Chung H, Wong S, Chan W, Li H. Depression Support Group: Participants' Evaluation and Perceived Effects. Hong Kong Pract 2006;28(1):14-23.
• Knubben K, Reischies FM, Adli M, Schlattmann P, Bauer M, Dimeo F. A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depression. Br J Sports Med 2007;41(1):29-33.
• Mather AS, Rodriguez C, Guthrie MF, McHarg AM, Reid IC, McMurdo ME. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: randomised controlled trial. Br J Psychiatry 2002;180:411-5.
• Sjosten N, Kivela SL. The effects of physical exercise on depressive symptoms among the aged: a systematic review. Int J Geriatr Psychiatry 2006;21(5):410-8.
• Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005;28(1):1-8.
• Singh NA, Stavrinos TM, Scarbek Y, Galambos G, Liber C, Fiatarone Singh MA. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. J Gerontol A Biol Sci Med Sci 2005;60(6):768-76.
• Mukaino Y, Park J, White A, Ernst E. The effectiveness of acupuncture for depression-a systematic review of randomised controlled trials. Acupunct Med 2005;23(2):70-6.
• Smith C, Hay P. Acupuntura para la depresión. (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). 2006.
• Leo RJ, Ligot J. . A systematic review of randomized controlled trials of acupuncture in the treatment of depression. J Affect Disord 2007;97(1-3):13-22.
• Allen JJ, Schnyer RN, Chambers AS, Hitt SK, Moreno FA, Manber R. Acupuncture for depression: a randomized controlled trial. J Clin Psychiatry 2006;67(11):1665-73.
• Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997;30 Suppl 2:129-34.
• National Prescribing Centre. St John's wort: is it effective in depression? In: MeReC Extra 2001.
• FDA Public Health Advisory. Risk of drug interactions with St John'S Wort and indinavir and other drugs. Internet. Center for Drug Evaluation and Research, 2007. Citado 1 octubre 2007; Disponible en: http://www.fda.gov/Cder/drug/advisory/stjwort.htm .
• Linde K, Mulrow C, Berner M, Egger M. Hierba de San Juan para la depresión. (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). 2007.
• Werneke U, Horn O, Taylor DM. How effective is St John's wort? The evidence revisited. J Clin Psychiatry 2004;65(5):611-7.